Integrative Epigenomic Analysis of Differential DNA Methylation in Urothelial Carcinoma

Overview

Journal Genome Med

Publisher Biomed Central

Specialty Genetics

Date 2015 Mar 27

PMID 25810763

Citations 20

Authors

Mattias Aine

Gottfrid Sjodahl

Pontus Eriksson

Srinivas Veerla

David Lindgren

Markus Ringner

Mattias Hoglund

Affiliations

Soon will be listed here.

Abstract

Background: Urothelial carcinoma of the bladder (UC) is a common malignancy. Although extensive transcriptome analysis has provided insights into the gene expression patterns of this tumor type, the mechanistic underpinnings of differential methylation remain poorly understood. Multi-level genomic data may be used to profile the regulatory potential and landscape of differential methylation in cancer and gain understanding of the processes underlying epigenetic and phenotypic characteristics of tumors.

Methods: We perform genome-wide DNA methylation profiling of 98 gene-expression subtyped tumors to identify between-tumor differentially methylated regions (DMRs). We integrate multi-level publically available genomic data generated by the ENCODE consortium to characterize the regulatory potential of UC DMRs.

Results: We identify 5,453 between-tumor DMRs and derive four DNA methylation subgroups of UC with distinct associations to clinicopathological features and gene expression subtypes. We characterize three distinct patterns of differential methylation and use ENCODE data to show that tumor subgroup-defining DMRs display differential chromatin state, and regulatory factor binding preferences. Finally, we characterize an epigenetic switch involving the HOXA-genes with associations to tumor differentiation states and patient prognosis.

Conclusions: Genome-wide DMR methylation patterns are reflected in the gene expression subtypes of UC. UC DMRs display three distinct methylation patterns, each associated with intrinsic features of the genome and differential regulatory factor binding preferences. Epigenetic inactivation of HOX-genes correlates with tumor differentiation states and may present an actionable epigenetic alteration in UC.

Citing Articles

FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression.

Okato A, Utsumi T, Ranieri M, Zheng X, Zhou M, Pereira L J Clin Invest. 2024; 134(2).

PMID: 38226620 PMC: 10786699. DOI: 10.1172/JCI169241.

The urothelial gene regulatory network: understanding biology to improve bladder cancer management.

Ramal M, Corral S, Kalisz M, Lapi E, Real F Oncogene. 2023; 43(1):1-21.

PMID: 37996699 DOI: 10.1038/s41388-023-02876-3.

A transcriptional network of cell cycle dysregulation in noninvasive papillary urothelial carcinoma.

Warrick J, Knowles M, Hurst C, Shuman L, Raman J, Walter V Sci Rep. 2022; 12(1):16538.

PMID: 36192513 PMC: 9529892. DOI: 10.1038/s41598-022-20927-9.

Multi-Omics Characterization of Tumor Microenvironment Heterogeneity and Immunotherapy Resistance Through Cell States-Based Subtyping in Bladder Cancer.

Hu R, Tao T, Yu L, Ding Q, Zhu G, Peng G Front Cell Dev Biol. 2022; 9:809588.

PMID: 35223867 PMC: 8864284. DOI: 10.3389/fcell.2021.809588.

DNA methylation-based profiling reveals distinct clusters with survival heterogeneity in high-grade serous ovarian cancer.

Wang J, Li J, Chen R, Yue H, Li W, Wu B Clin Epigenetics. 2021; 13(1):190.

PMID: 34645493 PMC: 8515755. DOI: 10.1186/s13148-021-01178-3.

References

Robbins M, Michalovich D, Hill J, Calver A, Medhurst A, Gloger I . Molecular cloning and characterization of two novel retinoic acid-inducible orphan G-protein-coupled receptors (GPRC5B and GPRC5C). Genomics. 2000; 67(1):8-18. DOI: 10.1006/geno.2000.6226. View

Feinberg A, Tycko B . The history of cancer epigenetics. Nat Rev Cancer. 2004; 4(2):143-53. DOI: 10.1038/nrc1279. View

Heyn H, Esteller M . DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet. 2012; 13(10):679-92. DOI: 10.1038/nrg3270. View

Van Batavia J, Yamany T, Molotkov A, Dan H, Mansukhani M, Batourina E . Bladder cancers arise from distinct urothelial sub-populations. Nat Cell Biol. 2014; 16(10):982-91, 1-5. DOI: 10.1038/ncb3038. View

Huang L, Pu Y, Hepps D, Danielpour D, Prins G . Posterior Hox gene expression and differential androgen regulation in the developing and adult rat prostate lobes. Endocrinology. 2006; 148(3):1235-45. PMC: 2276874. DOI: 10.1210/en.2006-1250. View

Lienert F, Wirbelauer C, Som I, Dean A, Mohn F, Schubeler D . Identification of genetic elements that autonomously determine DNA methylation states. Nat Genet. 2011; 43(11):1091-7. DOI: 10.1038/ng.946. View

Hinoue T, Weisenberger D, Lange C, Shen H, Byun H, van den Berg D . Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2011; 22(2):271-82. PMC: 3266034. DOI: 10.1101/gr.117523.110. View

Sturm D, Witt H, Hovestadt V, Khuong-Quang D, Jones D, Konermann C . Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012; 22(4):425-37. DOI: 10.1016/j.ccr.2012.08.024. View

Kundaje A, Kyriazopoulou-Panagiotopoulou S, Libbrecht M, Smith C, Raha D, Winters E . Ubiquitous heterogeneity and asymmetry of the chromatin environment at regulatory elements. Genome Res. 2012; 22(9):1735-47. PMC: 3431490. DOI: 10.1101/gr.136366.111. View

10.

Gandhi D, Molotkov A, Batourina E, Schneider K, Dan H, Reiley M . Retinoid signaling in progenitors controls specification and regeneration of the urothelium. Dev Cell. 2013; 26(5):469-482. PMC: 4024836. DOI: 10.1016/j.devcel.2013.07.017. View

11.

Wang G, Song J, Wang Z, Dormann H, Casadio F, Li H . Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature. 2009; 459(7248):847-51. PMC: 2697266. DOI: 10.1038/nature08036. View

12.

Coulson J . Transcriptional regulation: cancer, neurons and the REST. Curr Biol. 2005; 15(17):R665-8. DOI: 10.1016/j.cub.2005.08.032. View

13.

Peric-Hupkes D, van Steensel B . Linking cohesin to gene regulation. Cell. 2008; 132(6):925-8. DOI: 10.1016/j.cell.2008.03.001. View

14.

Wilhelm-Benartzi C, Koestler D, Houseman E, Christensen B, Wiencke J, Schned A . DNA methylation profiles delineate etiologic heterogeneity and clinically important subgroups of bladder cancer. Carcinogenesis. 2010; 31(11):1972-6. PMC: 2966555. DOI: 10.1093/carcin/bgq178. View

15.

Agger K, Cloos P, Christensen J, Pasini D, Rose S, Rappsilber J . UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature. 2007; 449(7163):731-4. DOI: 10.1038/nature06145. View

16.

Landan G, Mendelson Cohen N, Mukamel Z, Bar A, Molchadsky A, Brosh R . Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues. Nat Genet. 2012; 44(11):1207-14. DOI: 10.1038/ng.2442. View

17.

Guo G, Sun X, Chen C, Wu S, Huang P, Li Z . Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet. 2013; 45(12):1459-63. PMC: 7512009. DOI: 10.1038/ng.2798. View

18.

Cooper G, Stone E, Asimenos G, Green E, Batzoglou S, Sidow A . Distribution and intensity of constraint in mammalian genomic sequence. Genome Res. 2005; 15(7):901-13. PMC: 1172034. DOI: 10.1101/gr.3577405. View

19.

Sjodahl G, Lovgren K, Lauss M, Patschan O, Gudjonsson S, Chebil G . Toward a molecular pathologic classification of urothelial carcinoma. Am J Pathol. 2013; 183(3):681-91. DOI: 10.1016/j.ajpath.2013.05.013. View

20.

Westbrook T, Martin E, Schlabach M, Leng Y, Liang A, Feng B . A genetic screen for candidate tumor suppressors identifies REST. Cell. 2005; 121(6):837-48. DOI: 10.1016/j.cell.2005.03.033. View